Estimation of the warfarin dose with clinical and pharmacogenetic data.
By Teri E. Klein, Russ B. Altman, N. Eriksson, B. Gage, S. Kimmel, M-T M Lee, N. Limdi, D. Page, D. Roden, M. Wagner and 2 more. 2009
1,636 citations recorded by the source corpus.
BACKGROUND Genetic variability among patients plays an important role in determining the dose of warfarin that should be used when oral anticoagulation is initiated, but practical methods of using genetic information have not been evaluated in a diverse and large population. We developed and used an algorithm for estimating the appropriate warfarin dose that is based on both clinical and genetic data from a broad population base. METHODS Clinical and genetic data from 4043 patients were used to create a dose algorithm that was based on clinical variables only and an algorithm in which genetic information was added to the clinical variables. In a validation cohort of 1009 subjects, we evaluated the potential clinical value of each algorithm by calculating the percentage of patients whose predicted dose of warfarin was within 20% of the actual stable therapeutic dose; we also evaluated other clinically relevant indicators. RESULTS In the validation cohort, the pharmacogenetic algorithm accurately identified larger proportions of patients who required 21 mg of warfarin or less per week and of those who required 49 mg or more per week to achieve the target international normalized ratio than did the clinical algorithm (49.4% vs. 33.3%, P<0.001, among patients requiring ≤21 mg per week; and 24.8% vs. 7.2%, P<0.001, among those requiring ≥49 mg per week). CONCLUSIONS The use of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin produces recommendations that are significantly closer to the required stable therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach. The greatest benefits were observed in the 46.2% of the population that required 21 mg or less of warfarin per week or 49 mg or more per week for therapeutic anticoagulation.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Pharmacology, Medical & Health AI
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Medical & Health AI
- Matt Fredrikson
- Patrick Drew McDaniel
- Jack Dunn
- Michael P. Wellman
- Nicolas Papernot
- Arunesh Sinha
- Nathan Kallus
- Angela Zhou
Citations in the corpus
- Towards the Science of Security and Privacy in Machine Learning (2016, background): “This is especially important in applications like credit decisions or healthcare [106].”
- Model Inversion Attacks that Exploit Confidence Information and Basic Countermeasures (2015, background): “Computing systems increasingly incorporate machine learning (ML) algorithms in order to provide predictions of lifestyle choices [6], medical diagnoses [20], facial recognition [1], and more.”
- Policy Evaluation and Optimization with Continuous Treatments (2018, methodology): “Following the procedure set out in [9], we consider correct prediction as being within 10% of the therapeutic dose T ∗ i , since measurements of patient INR are inherently noisy and dose is adjusted until the patient INR presents within a target range.”
- A Survey of Privacy Attacks in Machine Learning (2020, background): “A global active attacker that is in a more favourable position can isolate the model parameter updates they receive from each participant.”
- Optimal trees for prediction and prescription (2018, background): “Its appropriate dose can vary by a factor of ten among patients and hence can be difficult to establish, with incorrect doses contributing to severe adverse effects [36].”